[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350253-105":59,"doc-detail-350253-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","dose-de-escalation-in-prostate-radiotherapy-using-an-mr-linac-in-2-fractions-destination-2-protocol-for-a-randomized-phase-iir-ideal2b-trial","Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2) - protocol for a randomised, phase II/R-IDEAL2b trial","","Stereotactic body radiotherapy for localized prostate cancer delivered on an MRI-guided linear accelerator enables highly conformal treatment. The DESTINATION 2 trial is a federated randomized phase II/R-IDEAL 2b study assessing whether de-escalating dose to prostate tissue, while maintaining high dose to MRI-visible tumor(s) in two fractions, reduces genitourinary adverse events within 12 weeks without compromising disease control. Two dose strategies are compared in 200 men worldwide.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dose-de-escalation-in-prostate-radiotherapy-using-an-mr-linac-in-2-fractions-destination-2-protocol-for-a-randomized-phase-iir-ideal2b-trial/350253/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dose-de-escalation-in-prostate-radiotherapy-using-an-mr-linac-in-2-fractions-destination-2-protocol-for-a-randomized-phase-iir-ideal2b-trial/350253.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of the DESTINATION 2 trial?","Question",{"text":113,"@type":114},"To evaluate whether de-escalating dose to prostate tissue while keeping a high dose to MRI-visible tumor(s) in two fractions reduces genitourinary treatment-related adverse events without compromising disease control.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are participants assigned to treatment arms?",{"text":118,"@type":114},"Two hundred men with localized, MRI-visible prostate cancer are randomized 1:1 to either uniform-dose MR-linac SBRT to whole prostate and seminal vesicles, or de-escalated SBRT with reduced whole-prostate dose plus a boosted dose to MRI-visible tumor(s).",{"name":120,"@type":111,"acceptedAnswer":121},"What is the primary endpoint?",{"text":122,"@type":114},"Absolute and relative risk reduction in acute grade 2+ genitourinary adverse events (CTCAE v5) within 12 weeks after completing radiotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350253,1790790337,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Protocol  \n Dose dE-eScalaTion IN prostATe  \nradIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase  \nII/R-IDEAL2b trial  \nSian Cooper  ,1,2 Sophie Alexander,1,2 Dylan Breitkreutz,3 Francis Casey,4 John Christodouleas,5 Mathijs G Dassen,6 Veronica Dell’acqua,5 Alex Dunlop,4 Trina Herbert,1 Pavlos Kolias,7 Adam Mitchell,4 Floris J Pos,6 Rosalyne Westley,1,2 Alison C Tree,1,2 Uulke A Van Der Heide,6 Danny Vesprini3  \nTo cite: Cooper S, Alexander S, Breitkreutz D, et al. Dose  \ndE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linacin 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. BMJ Open 2026;16:e111791 . doi:10 . 1136/ bmjopen-2025-111791  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2025-111791](bmjopen-2025-111791)) .  \nReceived 02 October 2025 Accepted 10 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Sian Cooper;  \n[sian.cooper@rmh.nhs.uk](sian.cooper@rmh.nhs.uk)  \nABSTRACT  \nIntroduction Stereotactic body radiotherapy (SBRT) delivered on an MRI-guided linear accelerator (MR-linac) enables highly conformal prostate cancer irradiation. The DESTINATION 2 trial is a federated, randomised phase II/RIDEAL 2b study evaluating whether de-escalating the dose to prostate tissue, while maintaining a high dose to MRIvisible tumour(s) in two fractions, reduces genitourinary (GU) treatment-related adverse events (AE) without compromising disease control in men with localised prostate cancer.  \nMethods 200 men worldwide with localised, MRI-visible prostate cancer will be randomised 1:1 to receive either (1) prescribed uniform dose MR-linac SBRT (27 Gy in two fractions to the whole prostate and seminal vesicles with 0 mm CTV-PTV margin) or (2) de-escalated SBRT (20 Gy in two fractions to whole prostate with 0 mm CTVPTV margin and 27 Gy in two fractions to MRI-visible tumour(s) with a 4 mm intraprostatic margin applied to the GTV. All treatments are delivered using MRI-guided adaptive Radiotherapy (MRIgRT) . The primary endpoint is the absolute and relative risk reduction in acute grade 2+GUAE (CTCAE v5) within 12 weeks of completing radiotherapy. Secondary endpoints include late GU AE, acute and late gastrointestinal (GI) AE, sexual AE, patientreported outcomes, dosimetry, technical feasibility and 2-year biochemical relapse-free survival.  \nEthics and dissemination This is a federated trial design in which each centre operates independently with its own sponsor, ethics committee approval and regulatory oversight. Each centre is responsible for obtaining and maintaining local ethics approval in accordance with their national and institutional requirements. The UK centre (The Royal Marsden NHS Foundation Trust) has received ethical approval from the East of England–Cambridge South Research Ethics Committee (REC reference: 24/EE/0163; IRAS:  \n338368) . Results will be disseminated via peer-reviewed publications and conference presentations.  \nTrial registration number NCT06638541.  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ Federated trial design enables parallel recruitment and independent oversight at each centre, with joint Bayesian analysis to overcome single-centre sample size limitations.  \n⇒ Co-enrolment to MOMENTUM registry facilitates standardised data capture across all participating centres.  \n⇒ Bayesian statistical framework with prespecified decision thresholds enables robust estimates of adverse events and early safety monitoring. Primary endpoint focus is AE reduction for patient benefit.  \n⇒ Trial adoption limited to centres with MR-Linac delivery platfor","cbCaiefMR6NIBsxl","https://ap.wps.com/l/cbCaiefMR6NIBsxl","pdf",973699,"English","# Abstract\n# Introduction\n# Methods\n# Ethics and dissemination\n# Strengths and limitations of this study","[{\"question\":\"What is the main purpose of the DESTINATION 2 trial?\",\"answer\":\"To evaluate whether de-escalating dose to prostate tissue while keeping a high dose to MRI-visible tumor(s) in two fractions reduces genitourinary treatment-related adverse events without compromising disease control.\"},{\"question\":\"How are participants assigned to treatment arms?\",\"answer\":\"Two hundred men with localized, MRI-visible prostate cancer are randomized 1:1 to either uniform-dose MR-linac SBRT to whole prostate and seminal vesicles, or de-escalated SBRT with reduced whole-prostate dose plus a boosted dose to MRI-visible tumor(s).\"},{\"question\":\"What is the primary endpoint?\",\"answer\":\"Absolute and relative risk reduction in acute grade 2+ genitourinary adverse events (CTCAE v5) within 12 weeks after completing radiotherapy.\"}]","Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2) - protocol for a randomised, phase II/R-IDEAL2b trial | PDF",1790088057,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2d5a2811da46450008f5e19697bd4d7.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a06b3866fda1062351f4ff24d6f6141e.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd3ff6848144c31f4a191ddc91db1e97.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/adbe338d8b7379f9e86f5b47ee82fe38.webp",980,1306]